Announcements
Trials
Browse
Landscape
Eligibility
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, B-Cell
×
pembrolizumab
×
Clear all
Filters
3
NCT03598608
2026-02-05
MK-4280-003
Merck Sharp & Dohme LLC
Phase 1/2
Completed
137 enrolled